Investigational New Drug (IND) Applications and Submissions

Obtaining Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) is the first step towards beginning your clinical trials in the United States. Getting here required hard work and a great Pre-IND Meeting strategy, but you still need FDA approval on your IND application before you can ship your drug across state lines and begin clinical trials.

The sooner you can begin your clinical trials, the sooner your product will be on the market. To prevent any hiccups in this process, your final IND submission must be error-free and contain all required information including animal pharmacology and toxicology studies, manufacturer and investigator information, along with detailed protocols for your upcoming clinical trials.

How to Meet IND Filing Requirements

Your IND application will request authorization from the FDA to administer an investigational drug/biological product to humans and must be approved before you transport your product across state lines to clinical sites. The requirements for an IND submission are complicated and can be hard to understand. ProPharma Group will work with you to make sure your IND application meets these stringent requirements and contains all of the following components:

  • Form FDA 1571 and 3674
  • Table of contents
  • Introductory statement
  • General investigational plan
  • Investigator’s brochure
  • Protocol(s): study protocol(s), investigator data, facilities data, Institutional Review Board (IRB)
  • Chemistry, manufacturing, and control (CMC) data, including environmental assessment or claim for the exclusion (assuming the draft of CMC information exists)
  • Nonclinical: pharmacology and toxicology data
  • Clinical: previous human experience
  • Additional information to support the IND filing

Together, we will carefully review the IND application, and our staff will provide you with a final copy that is FDA ready. The IND application will go into effect 30 days after the FDA receives the application (unless subject to a clinical hold), or earlier if the agency notifies the Sponsor that clinical trials can begin.

ProPharma Group will guide you through every step of the IND submission process and ensure your application is error-free to meet filing requirements and ensure a successful interaction with the FDA. To learn more about how ProPharma Group can help you develop a successful IND application for submission to the FDA, contact us today.

Contact Us

Need Help Navigating the Dynamic Regulatory Market to Bring Your Product Concept to Market?

Contact us to discover how 30+ years of regulatory experience using a strategic and scientific approach can deliver successful and expeditious outcomes.

Interested in gaining an industry edge? Let us help you stay current.

All fields are required.
There was a problem with your submission. Errors have been highlighted below.